Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors

Polish Journal of Pharmacology

Volumn 54, Issue 4, 2002, Pages 381-389

  Rogóz, Zofia ^a   Wróbel, Andrzej ^a   Dlaboga, Daniel ^a   Dziedzicka Wasylewska, Marta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adaptive changes; Dopamine D2 D3 receptors; Mirtazapine; Rats; Repeated treatment

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; AMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MESSENGER RNA; MIRTAZAPINE; QUINPIROLE; TRITIUM; DOPAMINE 3 RECEPTOR; DRD3 PROTEIN, RAT; DRUG DERIVATIVE; MIANSERIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BINDING; DRUG BINDING SITE; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OLFACTORY NERVOUS SYSTEM; RAT; RNA TRANSLATION; ANIMAL; AUTORADIOGRAPHY; BINDING SITE; BRAIN; METABOLISM; MOTOR ACTIVITY; WISTAR RAT;

ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BRAIN; MALE; MIANSERIN; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 0036385043     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. 2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology, 1998, 140, 470-477.
2. 2 receptor mRNA. Brain Res., 1991, 564, 203-219.
3. 3 receptor ligand. Eur. J. Pharmacol., 1993, 249, R9-R10.
4. Davis R., Wilder M.I.: Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs, 1996, 5, 389-402.
5. De Boer T., Maur G., Raitieri M., De Vos C.J., Wieringa J. Pinder R.M: Neurochemical and autonomic profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology, 1988, 27, 399-408.
6. De Boer T., Nefkens F., Van Helvoirt A., Van Delft A.M.L.: Differences in modulation of noradrenergic and serotonergic transmission by the alpha 2 adrenoceptor antagonist, mirtazapine, mianserin and idazoxan. J. Pharmacol. Exp. Ther., 1996, 277, 852-860.
7. 2 selective adrenoreceptor antagonist Org 3770 (Mirtazapine, Remeron) enhances noradrenergic and serotonergic neurotransmission. Hum. Psychopharmacol., 1995, 10, S107-S108.
8. 2 dopamine receptors in the rat caudate putamen. Brit. J. Pharmacol., 1998, 123, 833-838.
9. 1 and D:2 dopamine receptors in the rat brain. J. Neural Transm., 1997, 104, 515-524.
10. Fallon J.H., Loughin S.E., Ribak C.E.: The islands of Calleja complex of rat basal forebrain. III. Histochemical evidence for striatopalidal system. J. Comp. Neurol., 1983, 218, 91-120.
11. 2A/2C receptors in the sensitization to cocaine. J. Physiol. Pharmacol., 2001, 52, 471-481.
12. 3 receptors in the islands of Calleja of the rat using quantitive receptor autoradiography. Eur. J. Pharmacol., 1994, 261, 179-183.
13. Holm K., Markham A.: Mirtazapine. A review of its use in major depression. Drugs, 1999, 57, 607-631.
14. Ivanets N.N., Agibalova T.V.: Efficacy of mirtazapine in the treatment of alcoholism. Eur. Neuropsychopharmacol., 2001, 11, Suppl. 2, S72.
15. 3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiat., 2000, 5, 378-388.
16. 3 receptors. Synapse, 1993, 14, 90-95.
17. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Nat. Acad. Sci. USA, 1992, 89, 8155-8159.
18. Liappas J., Paparrigopoulos T., Tzavellas E., Christodoulou A.N.: Mirtazapine enhances alcohol detoxification. Eur. Neuropsychopharmacol., 2001, 11, Suppl. 2, S73.
19. Maj J.: Behavioural effects of antidepressant drugs given repeatedly on the dopaminergic system. In: Dopamine and Mental Depression. Eds. Gessa G.L., Serra G., Oxford Press, 1990, 193-196.
20. Maj J.: Antidepressants given repeatedly: pharmacological evaluation of their action. Pol. J. Pharmacol. Pharm., 1991, 43, 241-254.
21. 3 receptors in the rat brain. Eur. J. Pharmacol., 1998, 351, 31-37.
22. 2 receptors in the rat brain. Eur. J. Pharmacol., 1996, 304, 49-54.
23. 1-adrenergic, doparninergic and serotonergic receptors in brain. Hum. Psychopharmacol., 1999, 14, 333-344.
24. 1-adrenergic, dopamine and serotonin system. J. Neural Transm., 1999, 106, 197-211.
25. Maj J., Rogóz Z., Skuza G., Sowińska H.: The effect of repeated treatment with antidepressant drugs on the action of D-amphetamine and apomorphine in rat. In: Neuropharmacology '85. Eds. Kelemen K., Magyar K., Vizi E.S., Akadémiai Kiadó, Budapest, 1985, 133-139.
26. 2 agonist. J. Neural Transm.-Gen. Sect., 1989, 78, 1-8.
27. Mann J.J., Kapur S.: A dopaminergic hypothesis of major depression. Clin. Neuropharmacol., 1995, 18, Suppl. 1, S57-S65.
28. McGrath C., Burrows G.D., Norman T.R.: Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur. J. Pharmacol., 1998, 356, 121-126.
29. Nickolson V.J., Wieringa J.H., Van Delft A.M.L.: Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmied. Arch. Pharmacol., 1992, 319, 48-53.
30. Paxinos G., Watson C.: The Rat Brain Stereotayic Coordinates. Academic Press, Sydney, 1986.
31. Richou H., Ruimy P., Charbaut J., Delisle J.P., Brunner H., Patris M.: A multicentre, double-blind, clomipramine-controlled efficacy and safely study of Org 3770. Hum. Psychopharmacol., 1995, 10, 263-271.
32. 3 receptors in the rat brain differentiated by agonist and antagonist binding - an autoradiographic analysis. Naunyn-Schmied. Arch. Pharmacol., 1999, 359, 178-186.
33. 3 receptors. Pol. J. Pharmacol., 2001, 53, 571-576.
34. 1-adrenergic system. Neuropharmacology, 2001, 41, 360-368.
35. 1-adrenergic receptors. J. Physiol. Pharmacol., 2002, 53, 105-116.
36. 2 receptors. NeuroRaport, 1995, 6, 329-332.
37. Schatzberg A.F., Posner J.A., Rotshild A.J.: The role of dopamine in psychotic depression. Clin. Neuropharmacol., 1995, 18, Suppl. 1, S66-S73.
38. 3 receptor. Eur. J. Pharmacol., 1992, 225, 331-337.
39. 3 as a target for neuroleptics. Nature, 1990, 347, 146-151.
40. Willner P.: Dopaminergic mechanisms in depression and mania. In: Psychopharmacology: The Forth Generation of Progress. Eds. Bloom F.E., Kupfer D.J., Raven Press, New York, 1995, 921-932.
41. Willner P.: The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol., 1997, 12, Suppl. 3, S7-S14.
42. Zivkov M., de Jongh G.: Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum. Psychopharmacol., 1995, 10, 172-180.